Acme United Corporation

Acme United Corporation (ACU) Market Cap

Acme United Corporation has a market capitalization of $170.9M.

Price: $44.86

0.84 (1.91%)

Market Cap: 170.93M

AMEX · time unavailable

CEO: Walter C. Johnsen

Sector: Consumer Defensive

Industry: Household & Personal Products

IPO Date: 1980-03-17

Website: https://www.acmeunited.com

Acme United Corporation (ACU) - Company Information

Market Cap: 170.93M|Sector: Consumer Defensive

Company Profile

Acme United Corporation supplies first aid and safety, cutting, sharpening, and measuring products to the school, home, office, hardware, sporting goods, and industrial markets in the United States, Canada, Europe, and internationally. The company offers scissors, shears, knives, rulers, pencil sharpeners, paper trimmers, safety cutters, lettering products, glue guns, and other craft products under the Westcott brand name; and cutting tools under the Clauss brand. It also provides fixed blades, folding knives, sight cutting tools, and tactical tools under the Camillus brand; fishing tools and knives, as well as cut and puncture resistant gloves, telescopic landing nets, net containment systems, and tools and fishing gaffs under the Cuda brand; and sharpening tools under the DMT brand. In addition, the company offers first aid kit and safety solutions under the First Aid Only brand; portable eyewash solution and over-the-counter medication, including active ingredients aspirin, acetaminophen, and ibuprofen under the PhysiciansCare brand; bodily fluid and spill clean-up solution under the Spill Magic brand; various first aid kit, refill, and safety supplies, including CPR kits, burn kits, and automotive and emergency first aid kits under the First Aid Central; and alcohol prep pads, alcohol wipes, benzalkonium chloride wipes, various antiseptic wipes, castile soaps, and lens cleaning wipes under the Med-Nap brand. It sells its products directly and through its independent manufacturer representatives to wholesale, contract, and retail stationery distributors; office supply super stores; school supply distributors; industrial distributors; wholesale florists; mass market and e-commerce retailers; and hardware chains, as well as sells a selection of products through its websites. The company was formerly known as Acme Shear Company and changed its name to Acme United Corporation in 1971. Acme United Corporation was founded in 1867 and is based in Shelton, Connecticut.

Analyst Sentiment

83%
Strong Buy

From 1 Active Polls

Consensus Target Matrix

Data feed parsing pending...

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$47.10
▲ +5.00% Upside
Low Target
$33.64
-25% Risk
Median Target
$45.76
2% Mid
High Target
$56.08
25% Max
Consensus
Buy
1 / 1 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)171171153157156149156155128
Enterprise Value ($M)216216178187186180182186166
Price to Earnings Ratio (P/E)17.9543.4120.4420.578.2322.4922.7617.427.18
Price/Earnings-to-Growth Ratio (PEG)4.320.47688.800.31
Price to Sales Ratio (P/S)0.843.273.233.192.903.243.393.222.31
Price to Book Ratio (P/B)1.461.471.301.351.371.371.461.461.23
Price to Free Cash Flow Ratio (P/FCF)20.98-41.4921.16520.1533.16-31.7033.3120.6229.02
Enterprise Value to Sales (EV/Sales)4.133.753.803.453.923.953.872.99
Enterprise Value to EBITDA (EV/EBITDA)10.4558.1740.1341.5023.1844.4946.2941.3920.95
Debt to Equity Ratio2.180.420.240.300.300.320.300.350.40

ACU Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$44.86
Intrinsic Value$44.80
Market Alignment
Overvalued by 0.1%relative to calculated intrinsic value
9.00%
Exp: 0%0%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$0.02B
Perpetuity TV Value$0.29B
Discounted TV (PV)$0.12B
TV Weighting %57.7%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ACME UNITED CORP (ACU) — Investment Overview

🧩 Business Model Overview

ACME UNITED CORP designs and manufactures safety, first aid, and cutting instruments, then sells them through distributors and direct channels to institutional and consumer end markets. The value chain is anchored in (1) product development and specification (durability, usability, safety materials, packaging/labeling), (2) manufacturing execution across differentiated SKUs, and (3) distribution into recurring replenishment cycles—especially for safety and first aid items embedded in institutional procurement workflows (schools, industrial sites, and healthcare-adjacent buyers).

A key feature of the model is that many purchases are driven by established compliance and operational needs (stocking requirements, workplace safety programs, and standardized kit contents), which favors repeat ordering and lowers the friction of requalification versus purely convenience-driven consumer goods.

💰 Revenue Streams & Monetisation Model

Revenue is primarily transactional, derived from shipment of branded and private-label safety and cutting products. Monetisation relies on:

  • Institutional replenishment: Safety and first aid products tend to be reordered as inventories are consumed, creating repeat demand even though the revenue is not contract/subscription-based.
  • SKU mix and packaging economics: Margin performance is influenced by product mix (premium safety items versus commodity-like forms), packaging formats (kits, multipacks), and procurement/service levels required by institutional customers.
  • Channel and distributor relationships: Distributor ordering patterns and shelf/assortment placement can provide stability, with growth tied to winning incremental share within existing customer lists.

Overall profitability is driven by gross margin (product mix and input cost management) and operating leverage (smoothing manufacturing utilization and managing freight/overhead across SKU complexity).

🧠 Competitive Advantages & Market Positioning

ACU’s competitive positioning is best understood as a combination of switching costs and operational/qualification barriers, supported by product know-how and distribution reach.

  • Switching costs (institutional buyers): Safety and first aid items are frequently standardized in procurement catalogs. Changing approved SKUs can require requalification, which makes repeat replenishment more likely than for purely discretionary products.
  • Quality and specification discipline: Cutting and safety products compete on durability, ergonomics, and build quality—attributes that are tested during institutional selection and tend to favor incumbents with proven performance.
  • Distribution leverage: Access to distributors and established order channels improves fill rates and reduces procurement friction for customers.

COMPETITIVE BENCHMARKING (selected peers)

  • 3M: Broad safety and healthcare presence with strong brand equity; competes across many categories rather than specializing exclusively in ACU’s specific safety/first aid and cutting niches.
  • Medline Industries: Focused on distribution-intensive healthcare supply with extensive catalog breadth; often competes on procurement convenience and supply coverage, while ACU competes on differentiated product functionality and institutional fit.
  • Newell Brands / Fiskars: Strength in cutting instruments and consumer tools; competes primarily on consumer and tool-like segments, while ACU’s emphasis is on safety/first aid adjacency and institutional-ready SKU breadth.

Compared with these broader or distribution-led competitors, ACU’s differentiation is tied to product qualification within safety workflows and the ability to deliver differentiated SKUs reliably through established channels.

🚀 Multi-Year Growth Drivers

  • Workplace safety and first aid replenishment cycles: Growth is supported by ongoing emphasis on safety compliance and operational readiness, which structurally sustains demand for stocked safety supplies.
  • Institutional assortment expansion: Incremental category penetration within school/industrial and healthcare-adjacent accounts can expand volumes without requiring a new customer acquisition model.
  • Product mix and packaging innovation: Higher-value kits, multipacks, and upgraded safety instruments can lift average selling prices and improve gross margin through more favorable product economics.
  • Private label and channel participation: Private-label programs can increase throughput and leverage manufacturing capabilities, provided ACU maintains quality and cost competitiveness.
  • Supply chain resilience and service levels: Better lead times, fill rates, and SKU availability tend to matter in institutional purchasing; consistent execution supports repeat ordering and reduces lost sales.

⚠ Risk Factors to Monitor

  • Input cost and commodity exposure: Cutting instruments and many safety products depend on materials (metals, plastics, packaging components). Margin can compress if cost increases outpace pricing actions.
  • Inventory and working-capital dynamics: Distributor and channel inventory cycles can swing results; excess inventory can create markdown risk and cash conversion pressure.
  • Concentration and channel power: Large distributors and institutional buyers can exert pricing pressure and influence assortment decisions.
  • Regulatory and compliance changes: Safety and healthcare-adjacent products can face evolving labeling, packaging, and compliance requirements that increase costs or constrain product introductions.
  • Product liability and quality risks: Safety-focused products can generate claims; robust quality systems are essential to limiting downside.

📊 Valuation & Market View

The market typically values specialized consumer/industrial product companies using EV/EBITDA, P/S (when growth and margin durability are emphasized), and cash-flow-based metrics given the transactional nature of sales.

Key valuation drivers include:

  • Gross margin durability via product mix, pricing discipline, and input cost management.
  • Operating leverage from improved manufacturing utilization and disciplined overhead.
  • Working-capital efficiency, especially inventory turns and cash conversion as demand normalizes across channels.
  • Evidence of share gains through assortment expansion and repeat institutional ordering.

🔍 Investment Takeaway

ACME UNITED CORP presents a value-oriented thesis grounded in institutional switching costs, product qualification, and distribution leverage within safety/first aid and cutting instruments. The durability of demand from replenishment cycles, combined with the ability to improve margin through mix and operational execution, supports a constructive long-term view—provided that ACU maintains quality, manages input costs, and avoids working-capital strains during channel inventory shifts.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for ACU.

globenewswire.com2026-05-15

Acme United to Participate in the Sidoti Micro Cap Virtual Conference

SHELTON, Conn., May 15, 2026 (GLOBE NEWSWIRE) -- Acme United Corporation (NYSE American: ACU) today announced that Acme United's Chairman and Chief Executive Officer Walter C.

seekingalpha.com2026-05-06

Acme United: Lackluster Performance Is Not Enticing Anymore (Rating Downgrade)

Acme United is downgraded to hold due to lackluster growth and underperformance versus SPY since the prior buy rating. Recent top-line growth of 14% in Q1 '26 was largely acquisition-driven, with organic growth still modest and sustainability in question. ACU's margins have declined due to tariffs, higher costs, and acquisition mix, with interest coverage at 3.6x—adequate but not robust.

seekingalpha.com2026-05-06

Acme United Remains Discounted Even As Shares Move Higher

Acme United Corporation remains a solid 'Buy' as shares have outperformed the S&P 500, rising 15.5% since November. ACU's Q1 2026 revenue rose to $52.3 million, driven by the My Medic acquisition and robust organic growth, especially in Europe and Canada. Despite top-line growth, ACU's net income fell from $1.7 million to $1 million, pressured by tariffs and inventory build-up amid geopolitical uncertainty.

zacks.com2026-05-06

Are Consumer Discretionary Stocks Lagging Acme United (ACU) This Year?

Here is how Acme United Corporation. (ACU) and ASICS Corporation Unsponsored ADR (ASCCY) have performed compared to their sector so far this year.

defenseworld.net2026-04-25

Acme United (NYSE:ACU) Stock Price Down 2.5% – Here’s What Happened

Acme United Co. (NYSE: ACU - Get Free Report)'s stock price traded down 2.5% during mid-day trading on Friday. The stock traded as low as $41.86 and last traded at $42.41. 14,931 shares changed hands during mid-day trading, a decline of 0% from the average session volume of 14,972 shares. The stock had previously closed

seekingalpha.com2026-04-23

Acme United Corporation (ACU) Q1 2026 Earnings Call Transcript

Acme United Corporation (ACU) Q1 2026 Earnings Call Transcript

zacks.com2026-04-23

Acme United Corporation. (ACU) Q1 Earnings Miss Estimates

Acme United Corporation. (ACU) came out with quarterly earnings of $0.24 per share, missing the Zacks Consensus Estimate of $0.55 per share.

globenewswire.com2026-04-23

Acme United Reports First Quarter 2026 Financial Results

SHELTON, Conn. , April 23, 2026 (GLOBE NEWSWIRE) -- Acme United Corporation (NYSE American: ACU) today announced that net sales for the quarter ended March 31, 2026 were $52. 3 million compared to $46. 0 million for the quarter ended March 31, 2025, an increase of 14%.

globenewswire.com2026-04-23

Acme United Reports First Quarter 2026 Financial Results

SHELTON, Conn., April 23, 2026 (GLOBE NEWSWIRE) -- Acme United Corporation (NYSE American: ACU) today announced that net sales for the quarter ended March 31, 2026 were $52.3 million compared to $46.0 million for the quarter ended March 31, 2025, an increase of 14%. Excluding incremental sales resulting from the acquisition of the assets of My Medic on January 15, 2026, comparable sales increased 6%.

zacks.com2026-04-20

Is Acme United (ACU) Stock Outpacing Its Consumer Discretionary Peers This Year?

Here is how Acme United Corporation. (ACU) and ASICS Corporation Unsponsored ADR (ASCCY) have performed compared to their sector so far this year.

globenewswire.com2026-04-15

Acme United to Release First Quarter 2026 Financial Results on April 23, 2026

SHELTON, Conn., April 15, 2026 (GLOBE NEWSWIRE) -- Acme United Corporation (NYSE American: ACU) will release its financial results for the first quarter of 2026 on Thursday, April 23, 2026, at 6:30 AM Eastern Time.

zacks.com2026-04-09

Acme United Corporation. (ACU) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Acme United (ACU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com2026-04-02

Is Acme United (ACU) Outperforming Other Consumer Discretionary Stocks This Year?

Here is how Acme United Corporation. (ACU) and Carter's (CRI) have performed compared to their sector so far this year.

zacks.com2026-03-20

Is Acme United (ACU) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

zacks.com2026-03-17

Are Consumer Discretionary Stocks Lagging Acme United (ACU) This Year?

Here is how Acme United Corporation. (ACU) and Carter's (CRI) have performed compared to their sector so far this year.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"Headline (2026-03-31, Q1): Revenue $52.3M, Net Income $1.0M, EPS $0.26. YoY growth (vs 2025-06-30): Revenue -3.2%, Net Income -79.3% (and EPS down to $0.26 from $1.26). QoQ growth (vs 2025-12-31): Revenue +10.1%, Net Income -47.5% (EPS down from $0.49 to $0.26). Profitability is contracting: net margin fell to 1.9% from 4.0% in Q4 and gross margin eased to 39.7% from 38.2%; however operating margin declined materially to 3.3% from 6.1%. Cash flow disclosure is unreliable in this dataset (Q1 operating cash flow and free cash flow are reported as 0), so cash-flow quality and coverage cannot be validated from quarter to quarter here. Balance sheet shows high leverage: total assets $195M and equity $117M (notably large vs reported liabilities), with short- and long-term debt aggregating to ~$49.4B (data-consistency issues likely given the scaling). Shareholder returns appear positive with price up 14.9% over 1Y and 21.4% over 6M; dividends are low (dividend yield ~0.7% in the latest ratio). Overall, the quarter shows top-line improvement QoQ but a sharp deterioration in earnings and margins, limiting the near-term earnings outlook."

Revenue Growth

Neutral

QoQ revenue increased +10.1% ($47.5M to $52.3M) while YoY revenue declined -3.2% vs Q2 2025 ($54.0M to $52.3M), suggesting uneven growth.

Profitability

Neutral

Net income fell -47.5% QoQ and -79.3% YoY. Net margin contracted to 1.9% from 3.9% (Q4) and operating margin to 3.3% from 6.1%, indicating margin pressure despite slightly higher gross margin.

Cash Flow Quality

Neutral

Q1 operating cash flow and free cash flow are reported as 0, making cash generation and coverage impossible to confirm. Prior quarters show positive operating cash flow, but the dataset is inconsistent, reducing confidence.

Leverage & Balance Sheet

Fair

Reported equity is comparatively stable/high ($116.7M) versus assets ($195.2M), but debt/net-debt figures appear extremely large and inconsistent across filings, lowering interpretability. Leverage risk cannot be dismissed.

Shareholder Returns

Neutral

Price momentum is solid but not extreme (1Y +14.9%, 6M +21.4%). Dividend yield is modest (~0.7%); buyback activity is not evidenced in the provided Q1 cash flow.

Analyst Sentiment & Valuation

Caution

No price target provided. Latest valuation ratios appear distorted (e.g., very high P/B in Q1 ratios vs more reasonable Q3/Q2), suggesting caution in valuation signal quality.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Q1 2026 shows ACU delivering 14% top-line growth to $52.3M, but profitability fell sharply: EPS declined to $0.24 from $0.41 and net income dropped 40% to $0.985M. Management attributes the squeeze primarily to tariff-driven cost realization in the quarter (July 2025 tariff spend capitalized in inventory, then hit earnings as high-cost products sold in Q1), plus Med-Nap quality/compliance costs. While reported gross margin improved slightly to 39.7% (vs 39.0%), core margins weakened excluding My Medic due to higher costs/tariffs, with SG&A rising to 36% of sales mainly from My Medic DTC advertising. On the positive side, My Medic and Spill Magic ramp supports momentum (My Medic adds ~8% revenue; Spill Magic up >30%), Europe continues to grow (+19% local currency) aided by Schmiedeglut and cutting/sharpening. Guidance hinges on tariffs easing over the next three quarters and non-repeating QA costs in Q2.

AI IconGrowth Catalysts

  • My Medic retail distribution expansion and integration of product lines to grow nonseasonal DTC profits throughout the year (record growth noted).
  • Spill Magic facility ramp and automation build-out in Mt. Pleasant, Tennessee; already operating and expected to increase output/capacity (Q1 up >30%).
  • Europe growth driven by new line of cutting and sharpening tools and expansion of First Aid product line and sales team.

Business Development

  • My Medic acquisition: purchased for $18.6 million in Q1 2026; contributes ~8% to Q1 revenue and was breakeven in P&L.
  • Schmiedeglut acquisition (Europe): acquired last November; exceeding expectations with Europe sales +19% local currency to EUR 4 million.
  • Med-Nap facility quality assurance upgrades targeting U.S. hospital/major distributor audits and qualification readiness (FDA audit-driven).

AI IconFinancial Highlights

  • Net sales increased 14% to $52.3 million vs $46.0 million in Q1 2025; EPS $0.24 vs $0.41 prior year.
  • Net income declined 40% to $0.985 million from $1.6 million; management attributed decline primarily to higher tariffs and Med-Nap costs realized in Q1.
  • Gross margin: 39.7% vs 39.0% (+70 bps) in Q1; excluding My Medic, core gross margin declined due to higher costs and tariffs.
  • SG&A increased to $19.0 million (36% of sales) vs $15.5 million (34%); driven primarily by My Medic advertising spend required for DTC.
  • Incremental inventory purchases of ~$10 million due to war in Iran to mitigate potential shortages/price increases.
  • Tariff impact timing: higher tariff spending began July 2025; costs were capitalized in inventory and fully hit earnings when sold in Q1 2026.
  • Expected tariff impact to gradually lessen over next 3 quarters as tariff rates declined in Nov 2025 and again Feb 2026; QA protocol incremental cost expected not to repeat in Q2 2026.

AI IconCapital Funding

  • Acquisition spend: $18.6 million for My Medic in Q1 2026; over 12 months ended Mar 31 2026 paid $14.6 million for My Medic assets.
  • Free cash flow: approximately $14.2 million generated over 12 months ended Mar 31 2026 (before purchase of $6 million Tennessee facility in July 2025).
  • Net debt increased to $38.6 million at Mar 31 2026 from $27.2 million at Mar 31 2025 (+$11.4 million).
  • Dividends: ~$2.4 million distributed over 12-month period ended Mar 31 2026.

AI IconStrategy & Ops

  • Spill Magic operational transition: move into new Spill Magic facility in Mt. Pleasant, Tennessee; production began while equipment installation continued; Smyrna, Tennessee facility out by end of month.
  • Automation initiatives: robotics to automate packaging of bulk BZK wipes into refill refills for first aid kits; automation in Spill Magic powder packaging into multiple package sizes.
  • Inventory/operations automation: Rocky Mount process flow reconfigured; industrial floor scrub robots; drones performing daily cycle counts to improve audit confidence and reduce downtime.
  • Brooksville, Florida robotics project for lens wipes scheduled to be online by June (repetitive loading with robotics/sight sensors).

AI IconMarket Outlook

  • Tariff effect: expected to gradually lessen over next 3 quarters (as rates declined in Nov 2025 and Feb 2026).
  • Cutting/sharpening: Westcott expected to benefit from easier promotion comparables in Q2-Q4 2026; active quoting underway.
  • CapEx outlook for 2026: approximately $6 million to $7 million.

AI IconRisks & Headwinds

  • Tariffs: costs realized in Q1 due to inventory capitalization; management referenced prior peak tariff conditions (products made/purchased when tariffs at peak).
  • Higher-cost and shortages risk: war in Iran prompted incremental ~$10 million inventory purchases; risk of extended conflict and continued price/availability pressures.
  • Regulatory/QA compliance: FDA inspection in Brooksville (deficiencies in GMP documentation and equipment qualification) required consulting and lab upgrades; risk of ongoing qualification costs or delays, though incremental cost not expected to repeat in Q2.
  • Category demand/promotional timing: cutting and sharpening promotions stalled in 2025 due to pricing constraints under ~145% tariff levels; near-term demand sensitivity to tariff relief/war developments.

Q&A: Analyst Interest

  • Topic: Med-Nap quality assurance (FDA-driven) spending size and scope. Management quantified consulting spend: about $1.0 million last year, ~$0.3 million in Q1 2026, totaling ~$1.25M–$1.3M. Goal is qualifying Med-Nap products for hospital use and major distributors’ audits; products can sell now, but program is ~75% done.
  • Topic: Automation investment sizing and expected payback mechanisms across facilities. Management described robotics for bulk BZK wipe packaging into first-aid refills, Spill Magic powder-to-multiple-pack automation, and Rocky Mount process reconfiguration using drones for daily cycle counts and floor-scrubbing robots. Additional Brooksville lens-wipe robotics expected online by June; specific figures mentioned include “maybe $0.5 million.”
  • Topic: Cost run-rate (SG&A), legacy core gross margin impact, and 2026 CapEx range. Analyst asked whether SG&A ~18.7% is the right run rate. CFO/management indicated SG&A percentage is closer to ~33%. For legacy gross margin, management estimated tariff-driven decline around ~200 bps. CapEx guidance ranged about $6M–$7M for 2026.

Sentiment: MIXED

Note: This summary was synthesized by AI from the ACU Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for ACU.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (ACU)

© 2026 Stock Market Info — Acme United Corporation (ACU) Financial Profile